Methods and kits for the prognosis and treatment of prostate cancer
Provided herein are methods for the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient. In particular, gene expression levels of GCOM1, MEX3D, TRPM4, ATPAF1, PTRF, GLYATL1, FLNA, OBSCN, STRA13, WHSC1, ARFGAP3, KDM2A, FAM83H, CLDN7, CNOT6, and B3GNT9 are measured. Kits containing means for the measurement of gene expression as described herein and methods for treatment of prostate cancer are also provided.
1. A method for detecting and treating androgen-independent prostate cancer, comprising:
a) obtaining a biological sample from a subject, wherein said subject has or is suspected of having prostate cancer,
b) determining a first gene expression level of ATPAF1 in the biological sample,
c) comparing the first gene expression level determined at step b) with a reference value, wherein the reference value is determined in regard to a second gene expression level of ATPAF1 measured in samples taken from one or more healthy subjects,
d) detecting prostate cancer wherein a detected first gene expression level of ATPAF1 that is higher than the reference value indicates that the subject has androgen-independent prostate cancer, and
e) administering to said subject determined to have androgen-independent prostate cancer a treatment selected from the group consisting of surgery, radiation therapy, hormone therapy, ultrasound therapy, and chemotherapy.
2. The method according to claim 1 , wherein step b) further comprises
measuring the expression level of at least one or more of PTRF, MEX3D, TRPM4, GLYATL1, STRA13, WHSC1, ARFGAP3, FAM83H, CLDN7, CNOT6, GCOM1, PTRF, OBSCN, FLNA, B3GNT6, and KDM2A in said sample.
3. The method according to claim 1 , wherein step b) includes ten or more cycles of PCR amplification of the gene.
4. The method according to claim 1 , wherein said biological sample is a tumor sample.
5. The method according to claim 1 , wherein said subject has had a prostatectomy.